The present disclosure generally relates to implantable cardiac stimulation devices, and more particularly, to systems and methods for utilizing impedance data for operation of an implantable cardiac device configured to provide high voltage stimulation therapy.
Over the past several decades, large numbers of people have received implanted cardiac stimulation devices such as pacemakers and intra-cardiac defibrillators (ICDs). These devices include leads that are implanted so as to be positioned proximate the walls of the heart, e.g., implanted into the chambers of the heart. These leads typically serve two functions, to deliver therapeutic stimulation to the heart of the patient, and to sense cardiac activity and provide signals indicative thereof to a control unit so that the control unit can determine whether to deliver stimulation to the patient's heart. One problem that can occur over time is that the leads can become partially or fully fractured. In general, the leads are implanted into a very harsh environment where they are subject to repetitive mechanical stress and strain. Over a long time period, the lead can become fractured.
Fully fractured leads are generally incapable of delivering therapeutic stimulation to the heart of the patient. Partially fractured leads also provide problems in that they also may not be efficient at delivering therapeutic stimulation. Further, fractured leads can create noise on the lead. The noise signals may be interpreted by the control unit as indicative of heart activity. In worse case scenarios, the noise signals may be interpreted as a cardiac event that would by indicative of the need for stimulation to be applied to the heart. Consequently, lead fractures can result in the patient receiving heart stimulation when stimulation is not needed.
Unnecessary stimulation can potentially be very harmful to the patient. At a minimum, unnecessary stimulation can result in significant discomfort to the patient. Cardioversion or defibrillation waveforms, when delivered to a conscious patient, can be extremely painful. If the patient is periodically receiving unnecessary stimulations of this sort, the patient's quality of life can be significantly affected. There have been instances where patients have suffered psychological harm as a result of receiving such stimulations.
Certain parameters can be evaluated to assess the performance of a lead and to determine whether the lead has a partial or full fracture. One parameter is to measure the impedance of the lead. One difficulty with measuring impedance is that if the measurement is made at a time when high voltage stimulation is not being provided, e.g., the impedance measurement is made using a low voltage signal, the fracture may not be adequately detected. Often a partial fracture is difficult to detect at very low voltages so the source of noise which may result in inadvertent stimulation of the heart may go undetected.
Based upon the foregoing, there is a need for an improved way of sensing abnormalities with the leads of an implanted device that may result in spurious signals being received by the control unit thereby inducing the delivery of undesired therapeutic stimulations. To this end, there is a need for an analytic framework whereby impedance sensing on the lead may be performed in a manner that will more accurately determine whether there is a fracture or other physical problem with the lead that could be inducing noise.
A wide variety of systems, devices, methods, and processes comprising embodiments of the invention are described herein. In various embodiments, impedance data can be used as a basis for determining the operation of a high voltage confirmation system. In some embodiments, measurements of impedance associated with the high voltage lead can provide indication as to the condition of the lead. In some embodiments, faulty lead can yield impedance values that exceed a known threshold value. In some embodiments, such threshold value can be determined from a laboratory study of the lead under conditions that are similar to the operating conditions of implantable cardiac devices.
One embodiment of the invention is a system for differentiating noise from an arrhythmia of a heart, comprising a noise discriminator configured to receive an electrocardiogram (EGM) signal and to discriminate between an organized EGM signal and a chaotic EGM signal based at least in part on an impedance parameter associated with a lead that provides an electrical connection to the heart and a signal analyzer configured to determine whether a chaotic signal is caused by a disturbance in the lead.
Another embodiment is an implantable cardiac device, comprising a high voltage device configured to deliver a therapy signal to a heart when triggered, an electrical lead for connecting the high voltage device to the heart, an impedance measurement component configured to measure an electrical impedance associated with the electrical lead and a processor configured to provide a command for operation of the high voltage device based at least in part on a parameter associated with the measured electrical impedance.
Another embodiment is a method for operating an implantable cardiac device, comprising measuring an impedance value associated with at least one of a plurality of electrical leads for a high voltage device configured to provide a therapy signal, wherein the plurality of electrical leads are configured to be connected to a heart and deliver the therapy signal to the heart and generating a command for operation of the high voltage device based at least in part on the measured impedance value.
Another embodiment is a method for differentiating noise from an arrhythmia of a heart, comprising receiving an electrocardiogram (EGM) signal, measuring an impedance parameter associated with a lead that provides an electrical connection to the heart and determining whether the EGM signal is an organized signal or a chaotic signal based at least in part on the measured impedance parameter.
These and other aspects, advantages, and novel features of the present teachings will become apparent upon reading the following detailed description and upon reference to the accompanying drawings. In the drawings, similar elements have similar reference numerals.
The present disclosure generally relates to a high voltage confirmation system (HVCS) for implantable cardiac stimulation devices. More particularly, various embodiments of the HVCS can include a component configured to utilize one or more impedance and/or impedance-related parameters associated with the operation of the HVCS. Additional details about HVCS are available in a co-pending U.S. application Ser. No. 11/249,684 filed Oct. 12, 2005, titled “Method and Apparatus for Differentiating Lead Noise from Ventricular Arrhythmia” (Attorney Docket No. A05P4001) which is incorporated herein by reference in its entirety. Additional information on how cardiac therapy devices can be programmed to process impedance signals can be found in U.S. Pat. No. 7,010,347 titled “Optimization of Impedance Signals for Closed Loop Programming of Cardiac Resynchronization Therapy Devices” which is incorporated herein by reference in its entirety.
In one embodiment, as shown in
To sense left atrial and ventricular cardiac signals and to provide left chamber pacing therapy, the stimulation device 10 is coupled to a “coronary sinus” lead 24 designed for placement in the “coronary sinus region” via the coronary sinus ostium (OS) for positioning a distal electrode adjacent to the left ventricle and/or additional electrode(s) adjacent to the left atrium. As used herein, the phrase “coronary sinus region” refers to the vasculature of the left ventricle, including any portion of the coronary sinus, great cardiac vein, left marginal vein, left posterior ventricular vein, middle cardiac vein, and/or small cardiac vein or any other cardiac vein accessible by the coronary sinus.
Accordingly, an exemplary coronary sinus lead 24 is designed to receive atrial and ventricular cardiac signals and to deliver left ventricular pacing therapy using at least a left ventricular tip electrode 26, left atrial pacing therapy using at least a left atrial ring electrode 27, and shocking therapy using at least a left atrial coil electrode 28.
The stimulation device 10 is also shown in electrical communication with the patient's heart 12 by way of an implantable right ventricular lead 30 having, in this embodiment, a right ventricular tip electrode 32, a right ventricular ring electrode 34, a right ventricular (RV) coil electrode 36, and a superior vena cava (SVC) coil electrode 38. Typically, the right ventricular lead 30 is transvenously inserted into the heart 12 so as to place the right ventricular tip electrode 32 in the right ventricular apex so that the RV coil electrode will be positioned in the right ventricle and the SVC coil electrode 38 will be positioned in the superior vena cava. Accordingly, the right ventricular lead 30 is capable of receiving cardiac signals, and delivering stimulation in the form of pacing and shock therapy to the right ventricle.
As illustrated in
The housing 40 for the stimulation device 10, shown schematically in
To achieve left chamber sensing, pacing and shocking, the connector includes at least a left ventricular tip terminal (VL TIP) 44, a left atrial ring terminal (AL RING) 46, and a left atrial shocking terminal (AL COIL) 48, which are adapted for connection to the left ventricular tip electrode 26, the left atrial ring electrode 27, and the left atrial coil electrode 28, respectively.
To support right chamber sensing, pacing and shocking, the connector further includes a right ventricular tip terminal (VR TIP) 52, a right ventricular ring terminal (VR RING) 54, a right ventricular shocking terminal (RV COIL) 56, and an SVC shocking terminal (SVC COIL) 58, which are adapted for connection to the right ventricular tip electrode 32, right ventricular ring electrode 34, the RV coil electrode 36, and the SVC coil electrode 38, respectively.
At the core of the stimulation device 10 is a programmable microcontroller 60 which controls the various modes of stimulation therapy. As is well known in the art, the microcontroller 60 typically includes a microprocessor, or equivalent control circuitry, designed specifically for controlling the delivery of stimulation therapy and may further include RAM or ROM memory, logic and timing circuitry, state machine circuitry, and I/O circuitry. Typically, the microcontroller 60 includes the ability to process or monitor input signals (data) as controlled by a program code stored in a designated block of memory. The details of the design and operation of the microcontroller 60 are not critical to the invention. Rather, any suitable microcontroller 60 may be used that carries out the functions described herein. The use of microprocessor-based control circuits for performing timing and data analysis functions are well known in the art.
As shown in
The microcontroller 60 further includes timing control circuitry 79 which is used to control the timing of such stimulation pulses (e.g., pacing rate, atrio-ventricular (AV) delay, atrial interconduction (A-A) delay, or ventricular interconduction (V-V) delay, etc.) as well as to keep track of the timing of refractory periods, PVARP intervals, noise detection windows, evoked response windows, alert intervals, marker channel timing, etc., which is well known in the art.
The switch 74 includes a plurality of switches for connecting the desired electrodes to the appropriate I/O circuits, thereby providing complete electrode programmability. Accordingly, the switch 74, in response to a control signal 80 from the microcontroller 60, determines the polarity of the stimulation pulses (e.g., unipolar, bipolar, combipolar, etc.) by selectively closing the appropriate combination of switches (not shown) as is known in the art. In this embodiment, the switch 74 also supports simultaneous high resolution impedance measurements, such as between the case or housing 40, the right atrial electrode 22, and right ventricular electrodes 32, 34 as described in greater detail below.
Atrial sensing circuits 82 and ventricular sensing circuits 84 may also be selectively coupled to the right atrial lead 20, coronary sinus lead 24, and the right ventricular lead 30, through the switch 74 for detecting the presence of cardiac activity in each of the four chambers of the heart. Accordingly, the atrial (ATR. SENSE) and ventricular (VTR. SENSE) sensing circuits, 82 and 84, may include dedicated sense amplifiers, multiplexed amplifiers, or shared amplifiers. The switch 74 determines the “sensing polarity” of the cardiac signal by selectively closing the appropriate switches, as is also known in the art. In this way, the clinician may program the sensing polarity independently of the stimulation polarity.
Each sensing circuit, 82 and 84, preferably employs one or more low power, precision amplifiers with programmable gain and/or automatic gain control, bandpass filtering, and a threshold detection circuit, as known in the art, to selectively sense the cardiac signal of interest. The automatic gain control enables the device 10 to deal effectively with the difficult problem of sensing the low amplitude signal characteristics of atrial or ventricular fibrillation. The outputs of the atrial and ventricular sensing circuits, 82 and 84, are connected to the microcontroller 60 which, in turn, are able to trigger or inhibit the atrial and ventricular pulse generators, 70 and 72, respectively, in a demand fashion in response to the absence or presence of cardiac activity in the appropriate chambers of the heart.
For arrhythmia detection, the device 10 utilizes the atrial and ventricular sensing circuits, 82 and 84, to sense cardiac signals to determine whether a rhythm is physiologic or pathologic. As used herein “sensing” is reserved for the noting of an electrical signal, and “detection” is the processing of these sensed signals and noting the presence of an arrhythmia. The timing intervals between sensed events (e.g., P-waves, R-waves, and depolarization signals associated with fibrillation) are then classified by the microcontroller 60 by comparing them to a predefined rate zone limit (i.e., bradycardia, normal, low rate VT, high rate VT, and fibrillation rate zones) and various other characteristics (e.g., sudden onset, stability, physiologic sensors, and morphology, etc.) in order to determine the type of remedial therapy that is needed (e.g., bradycardia pacing, anti-tachycardia pacing, cardioversion shocks or defibrillation shocks, collectively referred to as “tiered therapy”).
Cardiac signals are also applied to the inputs of an analog-to-digital (A/D) data acquisition system 90. The data acquisition system 90 is configured to acquire intracardiac electrogram (IEGM) signals, convert the raw analog data into a digital signal, and store the digital signals for later processing and/or telemetric transmission to an external device 102. The data acquisition system 90 is coupled to the right atrial lead 20, the coronary sinus lead 24, and the right ventricular lead 30 through the switch 74 to sample cardiac signals across any pair of desired electrodes.
The microcontroller 60 is further coupled to a memory 94 by a suitable data/address bus 96, wherein the programmable operating parameters used by the microcontroller 60 are stored and modified, as required, in order to customize the operation of the stimulation device 10 to suit the needs of a particular patient. Such operating parameters define, for example, pacing pulse amplitude, pulse duration, electrode polarity, rate, sensitivity, automatic features, arrhythmia detection criteria, and the amplitude, waveshape and vector of each shocking pulse to be delivered to the patient's heart 12 within each respective tier of therapy.
Advantageously, the operating parameters of the implantable device 10 may be non-invasively programmed into the memory 94 through a telemetry circuit 100 in telemetric communication with the external device 102, such as a programmer, transtelephonic transceiver, or a diagnostic system analyzer. The telemetry circuit 100 is activated by the microcontroller by a control signal 106. The telemetry circuit 100 advantageously allows IEGMs and status information relating to the operation of the device 10 (as contained in the microcontroller 60 or memory 94) to be sent to the external device 102 through an established communication link 104.
In the preferred embodiment, the stimulation device 10 further includes a physiologic sensor 108, commonly referred to as a “rate-responsive” sensor because it is typically used to adjust pacing stimulation rate according to the exercise state of the patient. However, the physiological sensor 108 may further be used to detect changes in cardiac output, changes in the physiological condition of the heart, or diurnal changes in activity (e.g., detecting sleep and wake states). Accordingly, the microcontroller 60 responds by adjusting the various pacing parameters (such as rate, AV Delay, V-V Delay, etc.) at which the atrial and ventricular pulse generators, 70 and 72, generate stimulation pulses.
The stimulation device additionally includes a battery 110 which provides operating power to all of the circuits shown in
As further shown in
In the case where the stimulation device 10 is intended to operate as an implantable cardioverter/defibrillator (ICD) device, it must detect the occurrence of an arrhythmia, and automatically apply an appropriate electrical shock therapy to the heart aimed at terminating the detected arrhythmia. To this end, the microcontroller 60 further controls a shocking circuit 116 by way of a control signal 118. The shocking circuit 116 generates shocking pulses of low (up to 0.5 joules), moderate (0.5-10 joules), or high energy (11 to 40 joules), as controlled by the microcontroller 60. Such shocking pulses are applied to the patient's heart 12 through at least two shocking electrodes, and as shown in this embodiment, selected from the left atrial coil electrode 28, the RV coil electrode 36, and/or the SVC coil electrode 38. As noted above, the housing 40 may act as an active electrode in combination with the RV electrode 36, or as part of a split electrical vector using the SVC coil electrode 38 or the left atrial coil electrode 28 (i.e., using the RV electrode as a common electrode.
Cardioversion shocks are generally considered to be of low to moderate energy level (so as to minimize pain felt by the patient), and/or synchronized with an R-wave and/or pertaining to the treatment of tachycardia. Defibrillation shocks are generally of moderate to high energy level (i.e., corresponding to thresholds in the range of 5-40 joules), delivered asynchronously (since R-waves may be too disorganized), and pertaining exclusively to the treatment of fibrillation. Accordingly, the microcontroller 60 is capable of controlling the synchronous or asynchronous delivery of the shocking pulses.
In some embodiments, as shown in
As further shown in
In general, it will be appreciated that processors can include, by way of example, computers, program logic, or other substrate configurations representing data and instructions, which operate as described herein. In other embodiments, the processors can include controller circuitry, processor circuitry, processors, general purpose single-chip or multi-chip microprocessors, digital signal processors, embedded microprocessors, microcontrollers and the like.
Furthermore, it will be appreciated that in one embodiment, the program logic may advantageously be implemented as one or more components. The components may advantageously be configured to execute on one or more processors. The components include, but are not limited to, software or hardware components, modules such as software modules, object-oriented software components, class components and task components, processes methods, functions, attributes, procedures, subroutines, segments of program code, drivers, firmware, microcode, circuitry, data, databases, data structures, tables, arrays, and variables.
In some embodiments, as shown in
In certain situations, degradation of the lead can result in increase in impedance. In certain situations, however, a decrease in impedance can indicate some fault such as a possible short involving the lead or its connections. Thus, in examples described herein, detections of faulty lead can be based on some high and/or low impedance values or other values derived therefrom.
In some embodiments, one or more impedance threshold values can be set such that a condition can be triggered if a sampled impedance value goes beyond the set threshold value(s). For example, a Zhigh threshold 206 can be set such that the example sampled value 204c exceeds the threshold 206. In such a situation, an action associated with the HVCS can be triggered. An example of how such threshold can be set, as well as example triggered actions, are described below in greater detail.
In another example, a Zlow 208 can be set such that if a sampled impedance value goes below the threshold (none shown in
In some embodiments, as shown in
In some embodiments, such integration of impedance signal can be achieved by, for example, an integration circuit or via software using input sampled impedance values. The duration of the integration time interval(s) and/or any time intervals therebetween can be selected to achieve a desired range of Zdt values.
In some embodiments, as shown in
In some situations, use of Zdt may be less sensitive to Z signal fluctuations and provide a smoother trend indication of the impedance property of the high voltage lead. An example of how such threshold can be set, as well as example triggered actions, are described below in greater detail.
In some embodiments, various other quantities can be derived from Z and/or Zdt values. In a non-limiting example,
In some embodiments, as shown in
In some situations, use of such trend values may be less sensitive to Z signal fluctuations and provide a smoother trend indication of the impedance property of the high voltage lead. An example of how such threshold can be set, as well as example triggered actions, are described below in greater detail.
Other configurations are possible.
As shown in
In some embodiments, input for the reference 330 can be provided by a simulation component 336. Such simulation can be configured to predict various electrical properties (including impedance properties) associated with the high voltage lead. Such simulation data can be verified by data obtained empirically or by other studies.
In some embodiments, input for the reference 330 can be provides by laboratory data 338. For example, characteristic changes in one or more impedance parameters can be studied in simulated conditions in the laboratory. In the examples shows in
In some embodiments, various combinations of the example inputs 334, 336, and 338 can be used to form the reference 330. Other inputs are also possible.
As described herein, impedance data measured or derived can be compared to a reference. In some embodiments, such a reference includes one or more threshold values.
Based on such performance monitoring, an unacceptable or failure condition 360 can be identified (for example, at time t=Tf). Such failure condition can be correlated (depicted as an arrow 370) with the monitored impedance data 352 by, for example, identifying the value of the impedance parameter (depicted as threshold value 356) corresponding to the failure time Tf (depicted as time 354).
A wide variety of variations, however, are possible. For example, additional structural and/or functional elements may be added, elements may be removed or elements may be arranged or configured differently. Similarly, processing steps may be added, removed, or ordered differently. Accordingly, although the above-disclosed embodiments have shown, described, and pointed out the novel features of the invention as applied to the above-disclosed embodiments, it should be understood that various omissions, substitutions, and changes in the form of the detail of the devices, systems, and/or methods shown may be made by those skilled in the art without departing from the scope of the invention. Consequently, the scope of the invention should not be limited to the foregoing description, but should be defined by the appended claims.